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Abstract
Background: Increased expression of Eph receptor tyrosine kinases and their ephrin ligands has
been implicated in tumor progression in a number of malignancies. This report describes aberrant
expression of these genes in ovarian cancer, the commonest cause of death amongst gynaecological
malignancies.
Methods:  Eph and ephrin expression was determined using quantitative real time RT-PCR.
Correlation of gene expression was measured using Spearman's rho statistic. Survival was analysed
using log-rank analysis and (was visualised by) Kaplan-Meier survival curves.
Results: Greater than 10 fold over-expression of EphA1 and a more modest over-expression of
EphA2 were observed in partially overlapping subsets of tumors. Over-expression of EphA1
strongly correlated (r = 0.801; p < 0.01) with the high affinity ligand ephrin A1. A similar trend was
observed between EphA2 and ephrin A1 (r = 0.387; p = 0.06). A striking correlation of both ephrin
A1 and ephrin A5 expression with poor survival (r = -0.470; p = 0.02 and r = -0.562; p < 0.01) was
observed. Intriguingly, there was no correlation between survival and other clinical parameters or
Eph expression.
Conclusion: These data imply that increased levels of ephrins A1 and A5 in the presence of high
expression of Ephs A1 and A2 lead to a more aggressive tumor phenotype. The known functions
of Eph/ephrin signalling in cell de-adhesion and movement may explain the observed correlation of
ephrin expression with poor prognosis.
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Background
The sixteen vertebrate Eph receptors form the largest sub-
family of receptor tyrosine kinase (RTK) proteins. Activa-
tion and signalling by these receptors is mediated by
interaction with nine cell-surface counter receptors
known as ephrins. The ephrins are subdivided into an A
group which is glycosylphosphatidyl-inositol (GPI)
anchored and a B group of type I trans-membrane pro-
teins [1]. Eph proteins are also classified into A and B
groups depending on structural features and preferential
binding to either A or B type ephrins [2]. Eph and ephrin
proteins have important roles in facilitating de-adhesion
and cell movement, thereby playing critical roles in many
developmental processes [1,3,4]. Dysregulation of cell
adhesion and cell motility mechanisms have emerged as
key elements in tumor progression and metastasis and it
is notable that a large body of evidence details re-expres-
sion of both Eph and ephrin proteins at high levels in
malignancies including melanoma and colon, gastric,
breast, endometrial, and lung carcinomas [1,5].
EphB and ephrin B proteins have been implicated in both
normal and malignant epithelial tissues. EphB2 and
EphB3/ephrin B signalling regulates cell sorting in the
mature gut epithelium [6], counter gradients of EphB and
ephrin-B proteins regulating cell migration through con-
tact-mediated cell repulsion [7]. Over-expression of
EphB2, EphB4 and ephrin B1 is described in gastric, colon
and breast cancers [8-12].
The EphA/ephrin A system is also expressed in normal
and neoplastic epithelial tissues. Human EphA1 protein
was isolated from the hepatocellular carcinoma cell line
ETL-1 [13]. EphA1 is expressed in normal epithelial
organs [14]. Over-expression of EphA1 has been
described in prostate cancer [15], gastric cancers [16] and
a subset of colon, lung, liver and mammary carcinomas
[13,17]. EphA2 over-expression has been found in
oesophageal, breast and prostate cancers [18,19]. In non-
small cell lung cancer, high levels of EphA2 predicted
metastasis [20]. Ephrin A1 is the high affinity ligand for
both EphA1 [14] and EphA2. A study of EphA2 and
ephrin A1 in the CaCo2 colon cancer line suggests that
their interaction may be of importance in colon epithelial
structure and function [21].
We describe the expression of Eph and ephrin genes in a
series of ovarian cancers and non-malignant tissues using
quantitative real time RT-PCR. We show that elements of
both EphA/ephrin A and EphB/ephrin B signalling sys-
tems are over-expressed. A significant proportion of ovar-
ian tumors showed a > 5-fold increase in expression of
some Eph and/or ephrin proteins compared with non-
malignant tissues. EphA1 and EphA2 over-expression was
correlated with ephrin A1 suggesting that their interaction
may have a role in ovarian cancer progression. Intrigu-
ingly, over-expression of ephrin A1 and ephrin A5 mRNA
correlated with shortened survival whereas EphA1 and
EphA2 expression did not. The potential consequences of
this on ovarian cancer cell biology and clinical behaviour
are discussed.
Methods
Patient samples
Cancer specimens from twenty-four patients with
advanced ovarian cancer or primary peritoneal carcinoma
(PPC) were obtained after de-bulking surgery at the Royal
Brisbane Hospital (Queensland, Australia) after obtaining
informed consent and approval by the ethics committees
of the Queensland Institute of Medical Research, the Uni-
versity of Queensland and the Royal Brisbane Hospital.
These specimens were reviewed by Dr M Cummings,
Pathologist at the Royal Brisbane Hospital. The patient's
progress was monitored through follow-up visits with
their oncologists and CA 125 levels. Two normal ovaries,
one benign ovarian adenoma and one ovarian endometri-
otic cyst were tested as non-malignant controls.
RNA extraction and DNase digestion
Total RNA was isolated using the Qiagen RNeasy ® Midi
Kit (Qiagen Pty Ltd, Australia), according to the manufac-
turer's instructions. The initial part of the protocol was
modified so that approximately 200 mg of tissue was
crushed with a mortar and pestle in liquid nitrogen. RLT
buffer containing 10µl/mlβ-mercaptoethanol (βME) was
added and ground into the powdered tissue. Tissue was
transferred to a conical tube and homogenized with a
rotor/stator homogeniser (Polytron PT 1200, Kinematica,
Switzerland) for 2 × 30 second bursts. Samples were
digested with proteinase K (Qiagen Pty Ltd, Australia) and
extraction continued as recommended by the manufac-
turer.
Prior to cDNA synthesis, the optical density of all RNA
samples was measured and RNA integrity was assessed by
gel electrophoresis. These samples were then subjected to
DNase I treatment using RQ1 RNase-free DNase I
(Promega Pty Ltd, Australia) following manufacturer's
instructions.
cDNA synthesis
First strand cDNA was synthesized by reverse transcription
using Superscript III Reverse Transcriptase (Invitrogen Pty
Ltd, Australia). Briefly, DNase I-digested RNA was incu-
bated with 1.5 µl of 500 µg/ml oligo-dT30, 1.5 µl of 10 mM
dNTPs and 7 µl of diethylpyrocarbonate treated ddH2O
(DEPC-ddH2O) for 5 minutes at 65°C, chilled on ice and
spun quickly. This mixture was incubated with 6 µl of 5x
modified RT buffer (195 mM Tris-Cl pH 8.3, 375 mM
KCl), 1.5 µl of 0.1 M dithiothreitol (DTT), 40 U RNasinBMC Cancer 2006, 6:144 http://www.biomedcentral.com/1471-2407/6/144
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(Promega Corp., Australia) and 1.5 µl Superscript III for
60 minutes at 50°C. The reaction was inactivated by heat-
ing at 70°C for 15 minutes. cDNA was diluted 20-fold
prior to quantitative PCR.
Relative quantitation by real time PCR
Real-time PCR was carried out using Quantitect™ SYBR®
Green PCR Master Mix (Qiagen Pty Ltd, Australia) follow-
ing manufacturer's instructions. Briefly, 5 µl of diluted
cDNA was added to Quantitect™ SYBR® Green PCR Master
Mix. Forward and reverse primers were added to a final
concentration of 0.3 µM. Primer sequences are listed in
Table 1. A standard curve using cDNA serially diluted fur-
ther to 10-2, 10-4 and 10-6 and 18S rRNA primers was cre-
ated. All reactions were performed in duplicate. Real-time
PCR was carried out in a Corbett Research Rotor-Gene
3000™ (Corbett Research Pty Ltd, Australia). The PCR
cycling conditions included activation for 15 minutes at
95°C and 45 cycles of 30 seconds at 95°C, 30 seconds at
55°C, and 30 seconds at 72°C. Fluorescence data was
recorded at the end of each 72°C step. A DNA melt profile
was run subsequently from 72°C to 95°C with a ramp of
1°C/5 seconds. Fluorescence data was recorded continu-
ously during the melt profile. The relative expression lev-
els of EphA1, EphA2, EphB2, EphB3, EphB6, ephrin A1,
ephrin A5, and ephrin B1 were calculated using the stand-
ard curve generated from the 18S rRNA gene data.
Statistical methods
Correlation of gene expression was measured using Spear-
man's rho statistic. Receiver operating curve analysis was
used to determine the best cut-off value for survival classi-
fication. This cut-off value was then used to analyse sur-
vival by log-rank analysis and (was visualised by) Kaplan-
Meier survival curves. Hypotheses were tested using a 5%
significance level. All tests were two-sided.
Results
Patient characteristics
Twenty-three surgical samples were obtained from opera-
tive specimens removed at the first presentation of the
patient's disease and one additional sample was taken
from a patient with recurrent disease. All patients under-
went de-bulking surgery including total abdominal hys-
terectomy (TAH), bilateral salpingo-oophorectomy
(BSO) and omentectomy followed by carboplatin/paclit-
axel-based adjuvant chemotherapy. All patients in this
study presented with stage III/IV disease with poorly dif-
ferentiated serous papillary adenocarcinoma being the
predominant histological type. Seven patients presented
with primary peritoneal carcinoma. Median survival was
32 months with a range of 1–57 months. Individual clin-
ical details are presented in Table 2. In this series there was
no significant correlation between clinical parameters
(ascites, degree of differentiation, residual tumor, tumor
type or age) and survival.
Gene expression
Initially, the expression of 20 different Eph and ephrin
genes (EphA1-A8, EphB1-4 and 6, ephrin A1-5 and ephrin
B1-2) were screened by quantitative real time reverse tran-
scriptase polymerase chain reaction (Q-PCR) on two nor-
mal ovaries and ten ovarian cancer specimens. The
expression levels of EphA3, A4, A5, A7, A8, B1 and B4 and
of ephrin A2, A3, A4, B2 were relatively low in both nor-
mal and tumour samples and these genes were not consid-
ered further. Hence EphA1, EphA2, EphB2, EphB3,
EphB6, ephrin A1, ephrin A5 and ephrin B1 were selected
for further analysis in an additional fourteen tumor sam-
ples, one ovarian cyst and one ovarian adenoma. The
expression levels of the two normal ovaries and two non-
malignant pathological specimens were averaged and the
tumor expression data are presented relative to this aver-
age (hereafter referred to as non-malignant control).
Expression of EphA1, EphA2 and ephrin A1
Both EphA1 and EphA2 preferentially interact with ephrin
A1 and it was notable that all three were strongly
expressed in a proportion of tumors. As shown in Figure
1, EphA1 was the most dramatically over-expressed gene.
All tumors showed considerably higher EphA1 expression
levels than those in the normal control tissues. In 22/24
Table 1: Primers used in quantitative reverse transcriptase PCR
Gene (Acc. No.) Forward Primer (5' – 3') Reverse Primer (5' – 3')
18S rRNA (K03432) GACTCAACACGGGAAACCTC AGCATGCCAGAGTCTCGTTC
EphA1 (NM_005232) GTGGACACTGTCATAGGAGAAGG GGTCTTAATGGCCACAGTCTTG
EphA2 (NM_004431) GGGACCTGATGCAGAACATC AGTTGGTGCGGAGCCAGT
ephrin A1 (BC032698) CCGGAGAAGCTGTCTGAGAA GGTTTGGAGATGTAGTAGTAGCTGTG
ephrin A5 (NM_001962) TTGCACGTGGAGATGTTGAC GGTTGCTGCTGTTCCAGTAGA
EphB2 (NM_004442) GAAGGAGCTCAGTGAGTACAACG GCACCTGGAAGACATAGATGG
EphB3 (NM_004443) GGCCATAGCCTATCGGAAGT TCCCAGTAGGGTCGCTCTC
EphB6 (NM_004445) GAGCAGGAGGTACTAAATGCAA CCAGCTGGTCAAAATGAGG
ephrin B1 (BC052979) TGAAGGTTGGGCAAGATCC GGTTCACAGTCTCATGCTTGC
Genbank Accession Numbers are listed in parenthesis.BMC Cancer 2006, 6:144 http://www.biomedcentral.com/1471-2407/6/144
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tumor samples, EphA1 expression was more than five
times the level seen in non-malignant controls.
EphA2 expression in all tumors was comparable to or
higher than that observed in non-malignant control sam-
ples. More than half (15/23) of the tumors showed
expression levels of at least two-fold greater than those
seen in non-malignant control tissues, and five tumors
showed a level of over-expression of greater than 5-fold.
More than half (13/24) of the tumor specimens showed
greater than five-fold over-expression of ephrin A1 com-
pared to non-malignant control samples. However, it is
interesting to note that ephrin A1 correlated strongly with
EphA1 (r = 0.581; p = 0.005) but only weakly with EphA2
(r = 0.387; p = 0.063).
Expression analysis of EphB2, EphB3, EphB6 and ephrin 
B1
The B type Ephs and ephrins (shown in Fig 1) with higher
levels of expression in this series were EphB2, EphB3,
EphB6 and ephrin B1. In most samples, EphB2 expression
was comparable to or only slightly higher than the average
levels found in non-malignant control samples. Only
three tumors showed a greater than five-fold increase in
expression. A similar trend was also observed with EphB3.
In these cases some tumors appeared to have reduced
expression whilst others expressed higher levels including
five tumors with greater than five-fold increase in expres-
sion. EphB6 was also significantly over-expressed in
eleven tumors, these showing greater than five-fold over-
expression compared to control tissues.
Ephrin B1 was the most highly expressed ephrin in these
samples. Expression was also relatively high in non-malig-
nant samples with no tumors showing more than two-
fold over-expression. A significant correlation of expres-
sion was found between both EphB2 and EphB3 with
their ligand ephrin B1 (r = 0.411; p = 0.046 and r = 0.434;
p = 0.034 respectively).
Table 2: Individual clinical data for the 24 cases of ovarian cancer
Patient 
Number
ICD10* FIGO† Differentia
tion
Morpholo
gy‡
Tissue 
Sample
Months to 
Death
Censored§ Residual 
Tissue||
Ascites**
Tumor 1 C56 IIIC Poor PSC Omentum 13.88 0 0 4
Tumor 2 C48.2 IIIC Poor PSC Omentum 56.22 1 3 2
Tumor 3 C56 IIIC Poor PSC Omentum 32.99 0 1 2
Tumor 4 C48.2 IIIC Poor PSC Omentum 55.13 1 1 1
Tumor 5 C56 IIIC Poor PSC Omentum 28.06 0 2 1
Tumor 6 C56 IIIC Moderate PSC Ovary 44.05 0 1 2
Tumor 7 C56 IIIC Poor PSC Ovary 9.24 0 2 1
Tumor 8 C56 IIIB Poor PSC Ovary 38.32 0 0 1
Tumor 9 C48.2 IIIC Poor PSC Omentum 40.46 0 1 1
Tumor 10 C56 IIIC Unknown PSC Omentum 12.57 0 1 4
Tumor 11 C48.2 IIIC Poor PSC Ovary 10.33 0 1 2
Tumor 12 C56 IIIC Poor PSC Omentum 46.84 1 9 4
Tumor 13 C56 IV Poor PSC Ovary 1.25 0 1 0
Tumor 14 C56 IIIC Poor PSC Omentum 30.59 0 3 3
Tumor 15 C48.2 IIIC Poor PSC Omentum 45.30 1 3 5
Tumor 16 C56 IIIC Poor PSC Omentum 43.16 1 0 4
Tumor 17 C48.2 IIIC Poor SC Omentum 26.81 0 2 4
Tumor 18 C56 IIIC Poor PSC Omentum 41.81 1 0 1
Tumor 19 C56 IIIC Poor PSC Omentum 41.58 1 0 2
Tumor 20 C56 IIIC Poor PSC Ovary 31.78 0 0 0
Tumor 21 C56 IIIC Poor SC Ovary 24.67 0 0 4
Tumor 22 C48.2 IV Poor PSC Omentum 10.10 0 2 1
Tumor 23 C56 IIIC Poor SC Omentum 16.09 0 3 2
Tumor 24 C56 IIIB Poor SC Omentum 17.63 0 1 2
* ICD10 – International Classification of Disease v10: C48.2 – unspecified malignant neoplasm of peritoneum; and C56 – malignant neoplasm of 
ovary.
†FIGO – International Federation of Gynecology and Obstetrics Staging Classifications. Stage IIIB: involvement of both ovaries with peritoneal 
deposits < 2 cm; Stage IIIC: peritoneal deposits > 2 cm and/or retroperitoneal lymph node involvement; and Stage IV: involvement of both ovaries 
plus distant metastases.
‡Morphology: PSC = Papillary Serous Cystadenocarcinoma; and SC = Serous cystadenocarcinoma NOS.
§Censored: 0 = uncensored; and 1 = censored.
||Residual Tissue: 0 -nil; 1 -< 1 cm; 2 -1-2 cm; 3 – > 2 cm; and 9 – unknown.
**Ascites – 0 -nil; 1 – small (< 1L); 2 – medium (1–5L); 3 -large (> 5L); 4 – gross; and 9 – unknownBMC Cancer 2006, 6:144 http://www.biomedcentral.com/1471-2407/6/144
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Ephrin over-expression in ovarian cancer
Whilst neither EphA1 nor EphA2 over-expression corre-
lated significantly with patient survival, increased expres-
sion of both ephrin A1 and ephrin A5 correlated with
decreased survival. Ephrin A1, the preferential ligand for
EphA1 and a high affinity ligand for EphA2, was the high-
est expressed ephrin in these tumors and as shown in Fig
2A, the level of expression was strongly correlated with
poor survival (r = -0.470; p = 0.024). Both benign and
malignant specimens showed variable ephrin A5 expres-
sion with four and eight cancer specimens demonstrating
more than 5-fold and 2-fold over-expression of ephrin A5
respectively. Ephrin A5 preferentially interacts with
EphA2, A3, A5, A6, A7 and B2, of which only EphA2 and
EphB2 were expressed to any significant degree in the
tested normal or tumor samples. Notably, ephrin A5
expression was strongly correlated with shorter overall
survival (r = -0.562; p = 0.007).
Comparison of the Kaplan-Meier survival curves (Figs 2A-
C) of ephrin A5 with the next best candidate gene for poor
survival, ephrin A1, in conjunction with log-rank analysis,
shows that ephrin A5 is the dominating influence on over-
all survival. Notably, survival analysis of EphB and ephrin
B gene expression showed no significant correlations with
survival. Survival also did not correlate with pathological
categorization of tumour grade or cellularity.
Discussion
In this study we profiled Eph and ephrin gene expression
in twenty-four cases of ovarian carcinoma. Amongst the
Eph proteins the striking finding was the significant over-
expression of EphA1 and, to a lesser degree, EphA2 rela-
tive to the non-malignant controls. Whilst the increased
proportion of epithelial cells to stromal elements in
tumors explain a small increase in expression of EphA1,
the very high levels of expression in a significant propor-
tion of tumors indicates neoplastic over-expression of
EphA1. We assessed cellularity of the tumours as a possi-
ble correlate, and although such analysis is limited by
sampling error, we found no association of the Eph or
ephrin expression levels with tumour cellularity.
Interestingly, in a proportion of these cases, there was also
over-expression of ephrin A1, the preferred ligand for
both EphA1 and EphA2. Notably, expression of ephrin A1
and ephrin A5, high affinity ligands for EphA2, were
increased in the tumors with poorest survival. Whilst not
as dramatic, there was also statistically significant co-
expression of EphB2 or EphB3 with the EphB ligand,
ephrin B1. The co-expression of Ephs and ephrins on the
same cells suggests that tumor-tumor cell contact, could
autonomously activate the Eph/ephrin system thus pro-
moting tumour plasticity through the well described
capacity for Eph/ephrin signals to induce cell-cell repul-
sion [1,22,23]. Whilst all cases of high ephrin expression
also had high levels of Eph expression, the converse was
not true. This may suggest that high Eph expression pre-
cedes ephrin over-expression, which might explain why
ephrin expression is most highly correlated with tumor
aggressiveness. In keeping with Eph over-expression being
a priming event it is notable that EphA2 over-expression
causes malignant transformation in a normal mammary
epithelial cell line (MCF-10A) [19]. Interestingly, Han et al
previously reported that EphA2 over-expression is associ-
ated with poor prognosis in ovarian cancer [24]. This did
not emerge in our series, perhaps reflecting differences in
sample size. Notably, both ephrin A5 and ephrin A1 are
high affinity ligands for EphA2 perhaps indicating a link
between the two studies.
EphA1 has also been shown to be oncogenic in the classi-
cal 3T3 fibroblast assay [25], and co-expression of an
ephrin ligand could generate an autocrine loop. This has
been previously described where co-expression of ephrin
A1 and EphA2 was shown to have an autocrine effect
[26,27].
The finding that increased expression of ephrin A5 pre-
dicted poorer prognosis was an intriguing result as this
gene is generally not expressed at significant levels in epi-
thelial tissues (unpublished observations). Ephrin A5
Transcript number of Eph and ephrin genes in non-malignant  (N) and tumorigenic (T) tissues, relative to 108 copies of 18S  rRNA shown on a log scale Figure 1
Transcript number of Eph and ephrin genes in non-malignant 
(N) and tumorigenic (T) tissues, relative to 108 copies of 18S 
rRNA shown on a log scale. Whiskers show the 10th–90th 
percentile range while the shaded areas show the 25th–75th 
percentile range. The thin and heavy horizontal lines repre-
sent the median and the mean respectively.
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does not bind significantly to EphA1 [14] but has been
shown to activate EphA2 in human carcinoma cells [28].
In the current study we could not correlate mRNA levels
with protein expression on the biopsy samples, princi-
pally due to the lack of antibodies appropriate for immu-
nohistochemistry. The available antibodies are generally
suitable for Western blot analysis but not for immunohis-
tochemical applications. Using the ovarian cancer lines
OVCAR4 and OVCAR5 we were able to show that protein
expression (Western blot analysis) correlated precisely
with mRNA analysis. In the absence of suitable antibod-
ies, future studies should include extraction of tissue
lysates for Western blot analysis.
Conclusion
Our results provide evidence of increased expression of
Ephs and ephrins in ovarian cancer. This study provides
evidence that ephrin, but not Eph, expression predicts
poor prognosis in a group of ovarian cancer patients for
whom clinical parameters were not informative. This sug-
gests that co-expression of Eph and ephrin proteins may
be a significant event in tumor progression. Whilst this
study has yielded surprisingly strong correlations, a pro-
spective study of a much larger cohort is warranted to fur-
ther assess the use of ephrin expression as a useful
predictor of clinical outcomes in this disease.
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Plots showing association between high and low levels of ephrin A1 or ephrin A5, in conjunction, with survival Figure 2
Plots showing association between high and low levels of ephrin A1 or ephrin A5, in conjunction, with survival.
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